Consideration of height-based tobramycin dosing regimens for the treatment of adult cystic fibrosis pulmonary exacerbations.
Mehdi El HassaniChantale SimardSylvie PiloteIsabelle CloutierSara SoufsafAmélie MarsotPublished in: British journal of clinical pharmacology (2021)
Our results show that the models by Crass et al. and Alghanem et al. are appropriate for simulation-based applications to aid individualized dosing in our population and that height-based dosing regimens could be considered in cystic fibrosis patients.